Sangamo's Nasdaq Exit Triggers Trading Frenzy as Biotech Races to Secure Future

Sangamo Therapeutics shares surged 30% before Nasdaq suspension, moving to OTCQB amid financial struggles, partnership talks, and clinical progress in Fabry disease.

More than 61 million Sangamo Therapeutics shares changed hands on Monday — nearly eight times the daily average of 7.8 million — as investors scrambled ahead of the company's forced departure from the Nasdaq. The stock surged as much as 30% to around $0.18 in a final burst of volatility before trading was suspended Tuesday morning.

The biotech's descent to the OTCQB Venture Market marks the end of a prolonged struggle to meet the exchange's $1 minimum bid price requirement. Two compliance periods expired without a recovery, and while management has filed an appeal, the move does not lift the trading suspension. The shift to over-the-counter trading carries real consequences for shareholders: thinner liquidity, wider bid-ask spreads, and significantly reduced visibility among institutional investors.

Financial Lifelines and Strategic Urgency

Behind the scenes, Sangamo is fighting for survival. The company's March annual report flagged substantial doubt about its ability to continue as a going concern, warning that without fresh capital or successful partnerships, bankruptcy proceedings could be the worst-case outcome. A global investment bank has been retained to explore options, with particular focus on the hemophilia A program, where negotiations with potential collaborators are reportedly at an advanced stage.

The financial picture has improved modestly since the start of 2025. Sangamo has received over $130 million through a combination of milestone payments, licensing fees, and capital raises — including a key agreement with Eli Lilly for neurological applications. These inflows have bought management some breathing room as they pursue the deals that will determine the company's fate.

Pipeline Progress and Insider Activity

On the clinical front, Sangamo reports steady progress. The STAAR study for Fabry disease delivered positive 52-week data, and the FDA has confirmed a potential basis for accelerated approval. The rolling submission of the marketing application is underway and expected to be completed by summer. The company is also advancing its neurology pipeline, particularly in small fiber neuropathy.

The urgency of the situation was underscored by an insider transaction in late April: the senior vice president of corporate development sold more than half of his direct stake. Management has stressed that the exchange listing change has no impact on operations or clinical timelines.

All eyes are now on mid-May, when Sangamo is scheduled to report first-quarter 2026 results. Market participants are also awaiting concrete announcements on the partnership negotiations that could determine whether the gene therapy developer can secure its long-term future.